Gilead Sciences (GILD) Stock
Key stats
- Market cap
- $209.59B
- Price / Earnings ratio
- -54.3x
- EPS (TTM)
- -$3.10
- Volume
- Loading
- 52-week high
- $176.58
- 52-week low
- $116.88
- Dividend yield
- 1.95%
- Dividend amount (latest)
- $0.82
- EPS vs analyst estimate
- +15.4%Q3 FY25 · $2.47 vs $2.14
Source: third-party data provider, as of November 20, 2026
EPS estimate: analyst consensus
Compare with GILD
Recent news

Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
GILD

Gilead Sciences Maps Growth Beyond BIKTARVY With HIV, Cancer and Inflammation Drugs
Gilead Sciences Maps Growth Beyond BIKTARVY With HIV, Cancer and Inflammation Drugs
GILD

Suffolk Celebrates Completion of Gilead Sciences Research Center With Ribbon Cutting
Suffolk Celebrates Completion of Gilead Sciences Research Center With Ribbon Cutting
GILD

Gilead Sciences Bets on HIV Prevention Growth Despite $1.5 Billion Biktarvy Headwind
Gilead Sciences Bets on HIV Prevention Growth Despite $1.5 Billion Biktarvy Headwind
GILD
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 54.61
- MACD 12/26/9
- 3.58
- EMA 9 of MACD
- 4.30
- MACD histogram
- -0.72
- SMA 50
- $156.80
- Price above SMA 50
- EMA 50
- $158.47
- Price above EMA 50
- SMA 200
- $142.22
- Price above SMA 200
- EMA 200
- $143.83
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 19, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 14 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
Source: third-party data provider
Latest news

Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
GILD

Gilead Sciences Maps Growth Beyond BIKTARVY With HIV, Cancer and Inflammation Drugs
Gilead Sciences Maps Growth Beyond BIKTARVY With HIV, Cancer and Inflammation Drugs
GILD

Suffolk Celebrates Completion of Gilead Sciences Research Center With Ribbon Cutting
Suffolk Celebrates Completion of Gilead Sciences Research Center With Ribbon Cutting
GILD

Gilead Sciences Bets on HIV Prevention Growth Despite $1.5 Billion Biktarvy Headwind
Gilead Sciences Bets on HIV Prevention Growth Despite $1.5 Billion Biktarvy Headwind
GILD

Gilead Expands Access to Investigational Obeldesivir for Ebola Bundibugyo Virus Disease Through Voluntary Licensing
Gilead Expands Access to Investigational Obeldesivir for Ebola Bundibugyo Virus Disease Through Voluntary Licensing
GILD

Can Gilead Sciences' HIV Business Fuel Sustainable Long-Term Growth?
Can Gilead Sciences' HIV Business Fuel Sustainable Long-Term Growth?
GILD

3 Pharmaceutical Stocks That Offer Safety and Growth
3 Pharmaceutical Stocks That Offer Safety and Growth
GILD

Gilead Sciences Targets 200 Treatment Centers for Potential Anito-Cel Launch
Gilead Sciences Targets 200 Treatment Centers for Potential Anito-Cel Launch
GILD

Gilead Sciences Stock Hits a New All-Time High: Is it Still a Good Buy?
Gilead Sciences Stock Hits a New All-Time High: Is it Still a Good Buy?
GILD

The Top 5 Biotech Stocks I'd Buy Right Now Without Any Hesitation
The Top 5 Biotech Stocks I'd Buy Right Now Without Any Hesitation
GILD
News tone: automated (AI) classification of the article's content, not a price prediction.
About Gilead Sciences
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Daniel Patrick O'Day | Chairman & CEO | 1965 |
| Mr. Andrew D. Dickinson | Executive VP & CFO | 1970 |
| Ms. Johanna Mercier | Chief Commercial & Corporate Affairs Officer | 1970 |
| Dr. Dietmar P. Berger M.D., Ph.D. | Chief Medical Officer | 1969 |
| Ms. Erin E. Burkhart | Senior VP, Controller & Chief Accounting Officer | 1979 |
| Ms. Jacquie Ross C.F.A. | Senior Vice President of Treasury & Investor Relations | — |
| Ms. Keeley M. Cain Wettan | Executive VP, General Counsel of Legal & Compliance and Secretary | 1975 |
| Ms. Jyoti K. Mehra | Executive Vice President of Human Resources | 1976 |
| Dr. Linda Slanec Higgins Ph.D. | Senior Vice President of Research, Innovation & Portfolio | 1962 |
| Dr. Flavius Martin M.D. | Executive Vice President of Research | — |
Fundamentals
Valuation
Profitability
Trading
Dividend
Source: third-party data provider, as of November 20, 2026
Technical indicators
- RSI 14
- 54.61
- MACD 12/26/9
- 3.58
- EMA 9 of MACD
- 4.30
- MACD histogram
- -0.72
- SMA 50
- $156.80
- Price above SMA 50
- EMA 50
- $158.47
- Price above EMA 50
- SMA 200
- $142.22
- Price above SMA 200
- EMA 200
- $143.83
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 19, 2026. Technical data, not a recommendation.
Analyst views
14 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $131.00
- Average
- $179.64
- High
- $200.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -1.5 | +5.3 | ||||||||||
| 2022 | -5.4 | -11.8 | -1.3 | -0.6 | +7.5 | -4.6 | -4.2 | +6.5 | -5.0 | +25.9 | +10.7 | -2.3 |
| 2023 | -1.7 | -4.1 | +4.2 | -1.2 | -5.5 | +1.1 | -0.8 | +1.1 | -2.2 | +6.0 | -4.5 | +4.3 |
| 2024 | -6.0 | -7.8 | +1.3 | -10.5 | -1.9 | +8.2 | +10.8 | +3.3 | +5.2 | +5.8 | +3.4 | -1.8 |
| 2025 | +5.8 | +16.2 | -3.4 | -4.3 | +6.6 | +1.8 | +0.5 | -0.2 | -1.5 | +7.8 | +3.1 | -1.3 |
| 2026 | +16.7 | +4.2 | -7.1 | -6.7 | +2.1 | -3.6 | +3.4 | +11.6 | -0.6 | +15.7 | -2.2 |



